Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, while foods high in insoluble fiber, processed meat, spicy foods, dairy, and ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...